Papers in Cancer Drug Resistance
Page 4 · newest first
- Targeting BCL2 pathways in CLL: a story of resistance and ingenuityCancer Drug Resistance · 2023
- Supramolecular host-guest nanosystems for overcoming cancer drug resistanceCancer Drug Resistance · 2023
- Emerging roles of 3D-culture systems in tackling tumor drug resistanceCancer Drug Resistance · 2023
- Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategiesCancer Drug Resistance · 2023
- Unlocking antitumor immunity with adenosine receptor blockersCancer Drug Resistance · 2023
- Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivityCancer Drug Resistance · 2023
- Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistanceCancer Drug Resistance · 2023
- Drug resistance in glioblastoma: from chemo- to immunotherapyCancer Drug Resistance · 2023
- Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemiaCancer Drug Resistance · 2023
- A review of strategies to overcome immune resistance in the treatment of advanced prostate cancerCancer Drug Resistance · 2023
- Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomenaCancer Drug Resistance · 2023
- Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatmentCancer Drug Resistance · 2023
- Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7Cancer Drug Resistance · 2023
- Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemiaCancer Drug Resistance · 2023
- A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancerCancer Drug Resistance · 2023
- Primary and acquired resistance to first-line therapy for clear cell renal cell carcinomaCancer Drug Resistance · 2023
- The multifaceted role of extracellular vesicles in prostate cancer-a reviewCancer Drug Resistance · 2023
- The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunitiesCancer Drug Resistance · 2023
- Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapyCancer Drug Resistance · 2023
- New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancersCancer Drug Resistance · 2023
- Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effectsCancer Drug Resistance · 2023
- Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistanceCancer Drug Resistance · 2023
- Targeting regulated cell death pathways in acute myeloid leukemiaCancer Drug Resistance · 2023
- Immune checkpoint inhibitors in ovarian cancer: where do we go from here?Cancer Drug Resistance · 2023
- Anti-BCMA novel therapies for multiple myelomaCancer Drug Resistance · 2023
- miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic LeukemiaCancer Drug Resistance · 2023
- How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Cancer Drug Resistance · 2023
- Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistanceCancer Drug Resistance · 2023
- Targeting MYC-driven lymphoma: lessons learned and future directionsCancer Drug Resistance · 2023
- The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancerCancer Drug Resistance · 2023
- New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collectionCancer Drug Resistance · 2023
- Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironmentCancer Drug Resistance · 2023
- Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinomaCancer Drug Resistance · 2023
- Mitochondria in colorectal cancer stem cells - a target in drug resistanceCancer Drug Resistance · 2023
- Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery systemCancer Drug Resistance · 2023
- Importance of ROS1 fene fusions in non-small cell lung cancerCancer Drug Resistance · 2023
- The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducersCancer Drug Resistance · 2023
- Nano-TRAIL: a promising path to cancer therapyCancer Drug Resistance · 2023
- The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugatesCancer Drug Resistance · 2023
- Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitorsCancer Drug Resistance · 2023
- Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinomaCancer Drug Resistance · 2023
- Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancerCancer Drug Resistance · 2023
- Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cellsCancer Drug Resistance · 2023
- Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinomaCancer Drug Resistance · 2023
- Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activitiesCancer Drug Resistance · 2023
- Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistanceCancer Drug Resistance · 2022
- The complex relationship between multiple drug resistance and the tumor pH gradient: a reviewCancer Drug Resistance · 2022
- Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survivalCancer Drug Resistance · 2022
- Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistanceCancer Drug Resistance · 2022
- Lysosome-mediated chemoresistance in acute myeloid leukemiaCancer Drug Resistance · 2022